Перейти к главному меню навигации Перейти к основному контенту Перейти к нижнему колонтитулу сайта

№ 2 (2024)

ПСИХОФАРМАКОТЕРАПИЯ

Перепрофилирование лекарственных препаратов для лечения психических расстройств

https://doi.org/10.21265/PSYPH.2024.31.31.001

Опубликован 2024-06-30

  • Д.В. Пинахина
    • ,
  • Е.Д. Касьянов
    • ,
  • Я.В. Яковлева
    • ,
  • Г.В. Рукавишников
    • ,
  • А.О. Кибитов
    • ,
  • Г.Э. Мазо

Д.В. Пинахина
ФГБУ «Национальный медицинский исследовательский центр психиатрии и неврологии имени В.М. Бехтерева» Министерства здравоохранения Российской Федерации

Е.Д. Касьянов
ФГБУ «Национальный медицинский исследовательский центр психиатрии и неврологии имени В.М. Бехтерева» Министерства здравоохранения Российской Федерации

Я.В. Яковлева
ФГБУ «Национальный медицинский исследовательский центр психиатрии и неврологии имени В.М. Бехтерева» Министерства здравоохранения Российской Федерации

Г.В. Рукавишников
ФГБУ «Национальный медицинский исследовательский центр психиатрии и неврологии имени В.М. Бехтерева» Министерства здравоохранения Российской Федерации

А.О. Кибитов
ФГБУ «Национальный медицинский исследовательский центр психиатрии и неврологии имени В.М. Бехтерева» Министерства здравоохранения Российской Федерации; ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет имени акад. И.П. Павлова» Министерства здравоохранения Российской Федерации

Г.Э. Мазо
ФГБУ «Национальный медицинский исследовательский центр психиатрии и неврологии имени В.М. Бехтерева» Министерства здравоохранения Российской Федерации

Аннотация

Многофакторность этиологии психических расстройств и несовершенство диагностических подходов затрудняют разработку более эффективных лекарственных препаратов. Перепрофилирование ранее одобренных терапевтических агентов служит одним из перспективных подходов в поиске новых средств лечения психических расстройств. Это связано с тем, что, во-первых, данный подход является менее ресурсо- и экономически затратным по сравнению с иными направлениями разработки лекарственных средств. Во-вторых, методы поиска препаратов — кандидатов для перепрофилирования очень разнообразны и охватывают самые разные аспекты патогенеза психических расстройств. Исследовательская работа в области перепрофилирования лекарственных средств может расширить понимание механизмов развития психической патологии и в то же время способствовать оптимизации терапевтических и профилактических подходов в курации пациентов с данной группой расстройств. В настоящем обзоре кратко охарактеризовано разнообразие подходов к перепрофилированию препаратов c акцентом на методы in silico, а также приведены примеры успешных случаев перепрофилирования препаратов в психиатрии.

Ключевые слова

перепрофилирование лекарств в психиатрии, основные подходы к перепрофилированию, лекарственные мишени, генетические исследования

PDF

Библиографические ссылки

  1. Vos T., Lim S.S., Abbafati C. et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019 // The Lancet. – 2020. – Vol. 396 (10258). – Pp. 1204–1222. – https://doi.org/10.1016/S0140-6736(20)30925-9
  2. Riordan H.J., Cutler H.R. The death of CNS drug development: overstatement or Omen? // J Clin Stud. – 2011. – Vol. 3 – Pp. 12–15.
  3. Hughes J.P., Rees S., Kalindjian S.B., Philpott K.L. Principles of early drug discovery. // Br J Pharmacol. – 2011. – Vol. 162 (6). – Pp. 1239–1249. – https://doi.org/10.1111/j.1476-5381.2010.01127.x
  4. Blokhin I.O., Khorkova O., Saveanu R.V., Wahlestedt C. Molecular mechanisms of psychiatric diseases // Neurobiol Dis. – 2020. – Vol. 146. – Art. 105136. – https://doi.org/10.1016/j.nbd.2020.105136
  5. Caban A., Pisarczyk K., Kopacz K. et al. Filling the gap in CNS drug development: evaluation of the role of drug repurposing // J Mark Access Health Policy. – 2017. – Vol. 5 (1). – Art. 1299833. – https://doi.org/10.1080/20016689.2017.1299833
  6. Aminoff M.J., Boller F., Swaab D.F. Handbook of clinical neurology: Neurobiology of psychiatric disorders: foreword. – Vol. 106. – Amsterdam, Netherlands: Elsevier, 2012. – Pp. 2–760.
  7. Shemesh Y., Chen A. A paradigm shift in translational psychiatry through rodent neuroethology // Mol Psychiatry. –2023. – Vol. 28 (3). – Pp. 993–1003. – https://doi.org/10.1038/s41380-022-01913-z
  8. Truong T.T.T., Panizzutti B., Kim J.H., Walder K. Repurposing drugs via network analysis: Opportunities for psychiatric disorders // Pharmaceutics. – 2022. – Vol. 14 (7). – Art. 1464. – https://doi.org/10.3390/pharmaceutics14071464
  9. U.S. Food and Drug Administration. New Molecular Entity (NME) Drug and New Biologic Approvals. – Silver Spring, MD, USA: U.S. Food and Drug Administration, 2019.
  10. U.S. Food and Drug Administration. New Molecular Entity (NME) Drug and New Biologic Approvals. – Silver Spring, MD, USA: U.S. Food and Drug Administration, 2020.
  11. Silva M.C., Haggarty S.J. Human pluripotent stem cell-derived models and drug screening in CNS precision medicine // Ann N Y Acad Sci. – 2020. – Vol. 1471 (1). – Pp. 18–56. – https://doi.org/10.1111/nyas.14012
  12. Murteira S., Ghezaiel Z., Karray S. et al. Drug reformulations and repositioning in pharmaceutical industry and its impact on market access: reassessment of nomenclature // J Mark Access Health Policy. – 2013. – Vol. 1. – https://doi.org/10.3402/jmahp.v1i0.21131
  13. Wang S.M., Lee H.K., Kweon Y.S. et al. Overactive Bladder Successfully Treated with Duloxetine in a Female Adolescent // Clin Psychopharmacol Neurosci. – 2015. – Vol. 13 (2). – Pp. 212–214. – https://doi.org/10.9758/cpn.2015.13.2.212
  14. Deftereos S.N., Dodou E., Andronis C., Persidis A. From depression to neurodegeneration and heart failure: re-examining the potential of MAO inhibitors // Expert Rev Clin Pharmacol. – 2012. – Vol. 5 (4). – Pp. 413–425. – https://doi.org/10.1586/ecp.12.29
  15. Decherchi S., Cavalli A. Thermodynamics and kinetics of drug-target binding by molecular simulation // Chem Rev. – 2020. – Vol. 120 (23). – Pp. 12788–12833. – https://doi.org/10.1021/acs.chemrev.0c00534
  16. Dudley J., Berliocchi L. Drug repositioning: approaches and applications for neurotherapeutics // CRC press: Boca Raton. – 2017. – Vol. 1. – http://dx.doi.org/10.4324/9781315373669
  17. Jumper J., Evans R., Pritzel A. et al. Highly accurate protein structure prediction with AlphaFold // Nature. – 2021. – Vol. 596 (7873). – Pp. 583–589. – https://doi.org/10.1038/s41586-021-03819-2
  18. McNutt A.T., Francoeur P., Aggarwal R. et al. GNINA 1.0: Molecular docking with deep learning // J Cheminformatics. – 2021. – Vol. 13 (1). – Art. 43. – https://doi.org/10.1186/s13321-021-00522-2
  19. Jiang H., Wang J., Cong W. et al. Predicting Protein–Ligand docking structure with graph neural network // J Chem Inf Model. – 2022. – Vol. 62 (12). – Pp. 2923–2932. – https://doi.org/10.1021/acs.jcim.2c00127
  20. Mathai N., Kirchmair J. Similarity-based methods and machine learning approaches for target prediction in early drug discovery: Performance and scope // Int J Mol Sci. – 2020. – Vol. 21 (10). – Art. 3585. – https://doi.org/10.3390/ijms21103585
  21. Daina A., Michielin O., Zoete V. Swiss target prediction: updated data and new features for efficient prediction of protein targets of small molecules // Nucleic Acids Res. –2019. – Vol. 47 (W1). – Pp. W357–W364. – https://doi.org/10.1093/nar/gkz382
  22. Nickel J., Gohlke B.O., Erehman J. et al. SuperPred: update on drug classification and target prediction // Nucleic Acids Res. – 2014. – Vol. 42 (Web Server issue). – Pp. W26– W31. – https://doi.org/10.1093/nar/gku477
  23. Ochoa D., Karim M., Ghoussaini M. et al. Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs // Nat Rev Drug Discov. – 2022. – Vol. 21 (8). – Art. 551. – https://doi.org/10.1038/d41573-022-00120-3
  24. Miyagawa T., Tokunaga K. Genetics of narcolepsy // Hum Genome Var. – 2019. – Vol. 6 (1). – Pp. 1–8. – https://doi.org/10.1038/s41439-018-0033-7
  25. Casamassima F., Hay A.C., Benedetti A. et al. L-type calcium channels and psychiatric disorders: A brief review // Am J Med Genet B Neuropsychiatr Genet. – 2010. – Vol. 153B (8). – Pp. 1373–1390. – https://doi.org/10.1002/ajmg.b.31122
  26. Ostacher M.J., Iosifescu D.V., Hay A. et al. Pilot investigation of Isradipine in the treatment of bipolar depression motivated by genome-wide association // Bipolar Disord. – 2014. – Vol. 16 (2). – Pp. 199–203. – https://doi.org/10.1002/10.1111/bdi.12143
  27. Doggrell S.A., Hancox J.C. Ibutilide-recent molecular insights and accumulating evidence for use in atrial flutter and fibrillation Expert // Opin Investig Drugs. – 2005. – Vol. 14 (5). – Pp. 655–69. – https://doi.org/10.1517/13543784.14.5.655
  28. Pritchard J.L.E., O’Mara T.A., Glubb D.M. Enhancing the Promise of Drug Repositioning through Genetics // Front Pharmacol. – 2017. – Available at: https://www.frontiersin.org/articles/10.3389/fphar.2017.00896 (accessed February 21, 2023).
  29. So H.C., Lau A., Chau C.K.L., Wong S.Y. Translating GWAS findings into therapies for depression and anxiety disorders: Drug repositioning using gene-set analyses reveals enrichment of psychiatric drug classes // Genetics. – 2017. – https://doi.org/10.1101/132563
  30. de Jong S., Vidler L.R., Mokrab Y. et al. Gene-set analysis based on the pharmacological profiles of drugs to identify repurposing opportunities in schizophrenia // J Psychopharmacol Oxf Engl. – 2016. – Vol. 30 (8). – Pp. 826–830. – https://doi.org/10.1177/0269881116653109
  31. Gaspar H., Hübel C., Breen G. Drug Targetor: A web interface to investigate the human druggome for over 500 phenotypes // Bioinforma Oxf Engl. – 2018. – Vol. 35 (14). – Pp. 2515–2517. – https://doi.org/10.1093/bioinformatics/bty982
  32. Bell N., Uffelmann E., van Walree E. et al. Using genome-wide association results to identify drug repurposing candidates // Genetic and Genomic Medicine. – 2022. – https://doi.org/10.1101/2022.09.06.22279660
  33. Yetisgen-Yildiz M., Pratt W. Using statistical and knowledge-based approaches for literature-based discovery // J Biomed Inform. – 2006. – Vol. 39 (6). – Pp. 600–611. – https://doi.org/10.1016/j.jbi.2005.11.010
  34. Yetisgen-Yildiz M. A new evaluation methodology for literature-based discovery systems // J Biomed Inform. – 2009. – Vol. 42 (4). – Pp. 633–643. – https://doi.org/10.1016/j.jbi.2008.12.001
  35. Reay W.R., Atkins J.R., Carr V.J. et al. Pharmacological enrichment of polygenic risk for precision medicine in complex disorders // Sci Rep. – 2020. – Vol. 10 (1). – Art. 879. – https://doi.org/10.1038/s41598-020-57795-0
  36. Smith G.D., Ebrahim S. “Mendelian randomization”: can genetic epidemiology contribute to understanding environmental determinants of disease? // Int J Epidemiol. – 2003. – Vol. 32 (1). – Pp. 1–22. – https://doi.org/10.1093/ije/dyg070
  37. Walker V.M., Davey Smith G., Davies N.M., Martin R.M. Mendelian randomization: a novel approach for the prediction of adverse drug events and drug repurposing opportunities // Int J Epidemiol. – 2017. – Vol. 46 (6). – Pp. 2078–2089. – https://doi.org/10.1093/ije/dyx207
  38. McIntyre R.S., Rosenblat J.D., Nemeroff C.B. et al. Synthesizing the evidence for Ketamine and Esketamine in treatment-resistant depression: An International expert opinion on the available evidence and implementation // Am J Psychiatry. – 2021. – Vol. 178 (5). – Pp. 383–399. – https://doi.org/10.1176/appi.ajp.2020.20081251
  39. Millard L.A.C., Davies N.M., Timpson N.J. et al. MR-PheWAS: Hypothesis prioritization among potential causal effects of body mass index on many outcomes, using Mendelian randomization. // Sci Rep. – 2015. – Vol. 5. – Art. 16645. – https://doi.org/10.1038/srep16645
  40. Burgess S., Thompson S.G. Interpreting findings from Mendelian randomization using the MR-Egger method // Eur J Epidemiol. – 2017. – Vol. 32 (5). – Pp. 377–389. – https://doi.org/10.1007/s10654-017-0255-x
  41. So H.C., Chau C.K.L., Chiu W.T. et al. Analysis of genome-wide association data highlights candidates for drug repositioning in psychiatry // Nat Neurosci. – 2017. – Vol. 20 (10). – Pp. 1342–1349. – https://doi.org/10.1038/nn.4618
  42. Barbeira N.A., Dickinson S.P., Bonazzola R. et al. Exploring the phenotypic consequences of tissue specific gene expression variation inferred from GWAS summary statistics // Nat Commun. – 2018. – Vol. 9 (1). – Art. 1825. – https://doi.org/10.1038/s41467-018-03621-1
  43. Lamb J., Crawford E.D., Peck D. et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease // Science. – 2006. – Vol. 313 (5795). – Pp. 1929–1935. – https://doi.org/10.1126/science.1132939
  44. Méndez-Lucio O., Baillif B., Clevert D.A., Rouquié D., Wichard J. De novo generation of hit-like molecules from gene expression signatures using artificial intelligence // Nat Commun. – 2020. – Vol. 11 (1). – Art. 10. – https://doi.org/10.1038/s41467-019-13807-w
  45. Shayakhmetov R., Kuznetsov M., Zhebrak A., et al. Molecular Generation for Desired Transcriptome Changes with Adversarial Autoencoders // Front Pharmacol. – 2020. – Available at: https://www.frontiersin.org/articles/10.3389/fphar.2020.00269 (accessed January 30, 2023).
  46. Lüscher T. D., Schuch V., Beltrão-Braga P.C.B. et al. Drug repositioning for psychiatric and neurological disorders through a network medicine approach // Transl Psychiatry. – 2020. – Vol. 10 (1). – Pp. 1–10. – https://doi.org/10.1038/s41398-020-0827-5
  47. Ban T.A. Fifty years chlorpromazine: A historical perspective // Neuropsychiatric Disease and Treatment. – 2007. – Vol. 3 (4). – Pp. 495–500.
  48. Ferry L., Johnston J.A. Efficacy and safety of bupropion SR for smoking cessation: data from clinical trials and five years of postmarketing experience // Int J Clin Pract. – 2003. – Vol. 57 (3). – Pp. 224–230.
  49. Das J. Repurposing of drugs — the Ketamine story // J Med Chem. – 2020. – Vol. 63 (22). – Pp. 13514–13525. – https://doi.org/10.1021/acs.jmedchem.0c01193
  50. Sofia R.D., Harakal J.J. Evaluation of ketamine HCl for anti-depressant activity // Arch Int Pharmacodyn Ther. – 1975. – Vol. 214 (1). – Pp. 68–74.
  51. Krupitsky E.M., Grinenko A.Y. Ketamine Psychedelic Therapy (KPT): A review of the results of ten years of research // J Psychoactive Drugs. – 1997. – Vol. 29 (2). – Pp. 165– 183. – https://doi.org/10.1080/02791072.1997.10400185
  52. Berman R.M., Cappiello A., Anand A. et al. Antidepressant effects of ketamine in depressed patients // Biol Psychiatry. – 2000. – Vol. 47 (4). – Pp. 351–354. – https://doi.org/10.1016/s0006-3223(99)00230-9
  53. Baldessarini R.J., Wright V. et al. A double-blind placebo controlled study of Desipramine in the treatment of ADD: I. Efficacy // J Am Acad Child Adolesc Psychiatry. – 1989. – Vol. 28. – Pp. 777–784. – https://doi.org/10.1097/00004583-198909000-00022
  54. Angeles A.D.L., Fernando M.B., Hall N.A.L. et al. Induced Pluripotent Stem Cells in Psychiatry: An Overview and Critical Perspective // Biol Psychiatry. – 2021. – Vol. 90 (6). – Pp. 362–372. – https://doi.org/10.1016/j.biopsych.2021.04.008
  55. Sellgren C.M., Gracias J., Watmuff B. et al. Increased synapse elimination by microglia in schizophrenia patient-derived models of synaptic pruning // Nat Neurosci. – 2019. – Vol. 22 (3). – Pp. 374–385 – https://doi.org/10.1038/s41593-018-0334-7
  56. Kishi T., Ikuta T., Matsuda Y. et al. Pharmacological treatment for bipolar mania: A systematic review and network meta-analysis of double-blind randomized controlled trials // Mol Psychiatry. – 2022. – Vol. 27 (2). – Pp. 1136–1144. – https://doi.org/10.1038/s41380-021-01334-4
  57. Chen C.C., Zhou N., Hu N. et al. Acute effects of intravenous sub-anesthetic doses of Ketamine and intranasal inhaled Esketamine on suicidal ideation: A systematic review and meta-analysis // Neuropsychiatr Dis Treat. – 2023. – Vol. 19. – Pp. 587–599. – https://doi.org/10.2147/NDT.S401032
  58. Fountoulakis K.N., Tohen M., Zarate C.A. Lithium treatment of Bipolar disorder in adults: A systematic review of randomized trials and meta-analyses // Eur Neuropsychopharmacol. – 2022. – Vol. 54. – Pp. 100–115. – https://doi.org/10.1016/j.euroneuro.2021.10.003
  59. Masdrakis V.G., Baldwin D.S. Prevention of suicide by clozapine in mental disorders: Systematic review // Eur Neuropsychopharmacol. – 2023. – Vol. 69. – Pp. 4–23. – https://doi.org/10.1016/j.euroneuro.2022.12.0
  60. Mann J.J., Michel C.A., Auerbach R.P. Improving Suicide prevention through evidence-based strategies: A systematic review // Am J Psychiatry. – 2021. – Vol. 178 (7). – Pp. 611– 624. – https://doi.org/10.1176/appi.ajp.2020.20060864

Скачивания

Данные скачивания пока недоступны.